BMS-986482 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the study team for guidance.
What is the safety profile of BMS-986482 (Nivolumab, Opdivo, Relatlimab, Opdualag, BMS-986016, relatlimab-rmbw, rHuPH20) in humans?
Nivolumab, a component of BMS-986482, has been studied in various clinical trials and is generally considered safe, but it can cause side effects like fatigue, rash, itching, diarrhea, nausea, and weakness. Serious side effects are less common but can include low phosphate levels and low white blood cell counts. There is also a risk of hepatitis B reactivation in patients treated with PD-1/PD-L1 inhibitors like Nivolumab.12345
How is the drug BMS-986482 different from other cancer treatments?
BMS-986482 is unique because it is a combination of two immunotherapy drugs, nivolumab and relatlimab, which target different immune checkpoints to help the body's immune system fight cancer. Nivolumab targets the PD-1 receptor, while relatlimab targets the LAG-3 protein, making this combination a novel approach compared to other treatments that may only target one checkpoint.35678
What data supports the effectiveness of the drug BMS-986482 for cancer?
Nivolumab, a component of BMS-986482, has shown effectiveness in treating advanced cancers like melanoma and non-small cell lung cancer by improving survival rates and being better tolerated than some other treatments. Additionally, the combination of nivolumab and relatlimab has been approved for treating advanced melanoma, indicating its potential effectiveness in cancer treatment.36789
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This clinical trial is open to individuals with advanced solid tumors. Specific eligibility criteria are not provided, but typically participants must have a certain type and stage of cancer, meet health condition requirements, and may need to have tried other treatments first.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive BMS-986482 alone or in combination therapy for advanced solid tumors
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Nivolumab
- Relatlimab
- rHuPH20
Find a Clinic Near You
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Christopher Boerner
Bristol-Myers Squibb
Chief Executive Officer since 2023
PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis
Deepak L. Bhatt
Bristol-Myers Squibb
Chief Medical Officer since 2024
MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania